Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: over 30 + cutaneous t-cell + rates  Related to the article below (Last Update: 5/12/2008)

Allos Therapeutics Reports First Quarter 2008 Financial Results
FOXBusiness - May 7, 2008
RH1 is a novel, small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase, or DTD, which is over-expressed in many tumors, ...ALTH
Effect of Preemptive Epidural Analgesia on Cytokine Response and ...
RedOrbit, TX - May 9, 2008
Interleukin-2 also plays critical roles in the immunoregulation of metastatic disease, and is essential for the development of T-cell responses. ...
Source: Google News

Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients -
PL Zinzani, G Baliva, M Magagnoli, M Bendandi, G … - Journal of Clinical Oncology, 2000 - jcojournal.org
... patients with relapsed or refractory cutaneous T-cell lymphomas ... MF; n = 30) and
peripheral T-cell lymphoma unspecified ... mg/m 2 intravenously over 30 minutes for ...

Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor -
JE Gootenberg, FW Ruscetti, JW Mier, A Gazdar, RC … - Journal of Experimental Medicine, 1981 - Rockefeller Univ Press
... Cells previously a incubated for 30 min in 1 mM ... The combined supernates (S100) were
layered over a 38% sucrose cushion ... Cutaneous T cell lym- TCGF activity phoma ...

Treatment of refractory T-cell malignancies using gemcitabine -
S Sallah, JY Wan, NP Nguyen - British Journal of Haematology, 2001 - Blackwell Synergy
... The drug was administered intravenously over 30 min at a ... prolymphocytic leukaemia
(PLL), peripheral T-cell lymphoma and cutaneous T-cell lymphoma (CTCL ...

Systemic Therapy of Cutaneous T-Cell Lymphomas (Mycosis Fungoides and the Sezary Syndrome) -
PA Bunn, SJ Hoffman, D Norris, LE Golitz, JL … - Annals of Internal Medicine, 1994 - annals.highwire.org
... These interferons offered no major advantages over interferons, so they ... In:
International Symposium on Cutaneous Lymphoma ... Copenhagen, Denmark, 28-30 October ...

… combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma -
JJ Scarisbrick, FJ Child, A Clift, R Sabroe, SJ … - British Journal of Dermatology, 2001 - Blackwell Synergy
... indolent lymphoma and typically presents with cutaneous patches and ... may progress
to tumours or erythroderma over many years. ... a median survival of only 30 months ...

Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in … -
SL Gottlieb, JT Wolfe, FE Fox, BJ DeNardo, WH … - J Am Acad Dermatol, 1996 - ncbi.nlm.nih.gov
... is currently used to treat cutaneous T-cell lymphoma (CTCL ... are available regarding
overall response rates and durability ... RESULTS: Thirty-one of 41 patients (76 ...

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients -
PL Zinzani, M Magagnoli, M Bendandi, G Fraternali … - Annals of Oncology, 1998 - Springer
... and admin- istered intravenously over 30 minutes ... a higher overall response rate compared
with ... Combined modality treatment of cutaneous T cell lymphoma: Results ...

Cutaneous T Cell Lymphoma: Update of Treatment -
HS Zackheim, T Cutaneous, HS Zackheim - Logo, 1999 - content.karger.com
... Doses over 25 mg are best given by injection ... Crain WR: Topical carmustine (BCNU)
for cutaneous T-cell lymphoma ... term follow-up observations in thirty-one patients ...

Aggressive Cutaneous NK and NK-like T-Cell Lymphomas: Clinicopathologic, Immunohistochemical, and … -
Y Natkunam, BR Smoller, JL Zehnder, RF Dorfman, … - The American Journal of Surgical Pathology, 1999 - ajsp.com
... then slowly cooled to 37?C over 30 min using ... of 12 cases showed high proliferation
rates (40% or ... 28,29 Approximately 10% of cutaneous T-cell lymphomas harbor ...

Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for … -
R Russell-Jones - Br J Dermatol, 2000 - Blackwell Synergy
... reported a median survival of over 100 months in ... rates of approximately 30%, 29 ,
30 but morbidity ... high, particularly in patients with cutaneous ulceration, or ...

Source: Google Scholar

Rates Of Cutaneous T-Cell Lymphoma Increase Over 30 Years
The cancer known as cutaneous T-cell lymphoma became substantially more common in the United States between 1973 and 2002, according to a report in the July issue of Archives of Dermatology, one of the JAMA/Archives journals. The rates of the disease vary by race, sex and geographic area.

Cutaneous T-cell lymphoma occurs when certain cells of the lymph system (called T lymphocytes) become cancerous and affect the skin. The term covers several types of lymphoma, according to background information in the article. The nationwide rates of the disease were last documented in 1992.
Vincent D. Criscione, A.B., and Martin A. Weinstock, M.D., Ph.D., of the VA Medical Center, Rhode Island Hospital, and Brown University, Providence, R.I., used data from 13 cancer registries of the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to describe incidence trends in cutaneous T-cell lymphoma from 1973 through 2002.

A total of 4,783 cases were identified in the 30-year period, a rate of 6.4 per million persons and a total of 0.14 percent of all cancers and 3.9 percent of non-Hodgkin's lymphomas. The overall incidence increased each decade, was higher among blacks than whites and among men than women, increased substantially with age, and varied geographically. The San Francisco registry had the highest rates - 9.7 per million white individuals and 10.8 per million black individuals - while the Iowa registry had the lowest, with 3.7 per million white individuals and 5.8 per million among blacks.

"The geographic differences in incidence are substantial even after controlling for race. Incidence is correlated with high physician density and several indexes of socioeconomic status such as median family income, percentage of the population with a bachelor's degree or higher and median home value," the authors write. "These geographic differences in incidence may be related, to some degree, by differences in access to medical care."

Changes and ambiguities in classifications and coding may be partially responsible for the increase in incidence over time, the authors note, as may improved detection and advances in medical technology. "An epidemiological investigation using population-based data is important to better understand this disorder," they conclude. However, "these data may be useful in planning public health strategies, identifying risk factors and understanding the etiology of this cancer so that it may some day be prevented."
Arch Dermatol. 2007;143(7):854-859
http://www.archderm.ama-assn.org

This project was funded by a grant from the Cutaneous Lymphoma Foundation. Dr. Weinstock was supported by grants from the Department of Veterans Affairs, Office of Research and Development, Washington, D.C., and from the National Cancer Institute, Bethesda, Md.

Editorial: Patients Helping to Solve Disease's Mystery

Scientists have been attempting for 200 years to uncover the underlying causes of cutaneous T-cell lymphoma, and while the disease remains mysterious, dermatologists and patients have begun working together to understand it, writes Stuart R. Lessin, M.D., of the Fox Chase Cancer Center, Philadelphia, in an accompanying editorial.

"Many etiologic factors have been advanced and studied, but none have been conclusive," Dr. Lessin writes. "These have included occupational exposures, viruses (Epstein-Barr virus, human T-lymphotropic virus 1 and human herpesvirus 6) and bacteria (staphylococcal superantigens)."

"While the increased incidence of cutaneous T-cell lymphoma remains unexplained, it demonstrates the increasing importance of the role of the dermatologist to remain at the forefront of diagnosis and treatment" of the disease, Dr. Lessin continues.

Arch Dermatol. 2007;143(7):916-918
http://www.archderm.ama-assn.org

Dr. Lessin serves as chairman of the Medical Advisory Board and as a member of the Board of Directors of the Cutaneous Lymphoma Foundation, the organization that funded the project that is the subject of this editorial.
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.